"The voice for cancer physicians and their patients in Massachusetts."
The U.S. Food and Drug Administration approved selumetinib (Koselugo; AstraZeneca) for neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurocfibromas (PN). Read full press release.
Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451
Waltham, MA. 02451